Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis.

ABSTRACT:

Background

Cystic fibrosis (CF) leads to pancreatic endocrine dysfunction with progressive glycemic disturbance. Approximately 30%-50% of people with CF eventually develop CF-related diabetes (CFRD). Pre-CFRD states progress from indeterminant glycemia (INDET) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Screening guidelines recommend inconvenient annual 2-hour oral glucose tolerance tests (OGTTs), beginning at age 10 years. More efficient methods, such as hemoglobin A1C (HbA1c), have been evaluated, but only limited, relatively small studies have evaluated the association between HbA1c and pre-CFRD dysglycemic states.

Objective

To determine whether HbA1c is an appropriate screening tool for identifying patients with pre-CFRD dysglycemia to minimize

SUBMITTER: Darukhanavala A 

PROVIDER: S-EPMC8059836 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature